[Activated protein C resistance syndrome].
Souto
J C
JC
Unitat d'Hemostasia i Trombosi, Hospital de la Santa Creu i Sant Pau, Barcelona.
Fontcuberta
J
J
D000925:Anticoagulants / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000097:blood; D000991:Antithrombins / Q000172:deficiency; D001777:Blood Coagulation / Q000502:physiology; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects; D004789:Enzyme Activation; D005165:Factor V / Q000737:chemistry / Q000235:genetics / Q000502:physiology; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood; D015995:Prevalence; D011486:Protein C / Q000502:physiology*; D018455:Protein S Deficiency / Q000150:complications; D012189:Retrospective Studies; D013577:Syndrome; D019851:Thrombophilia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D013924:Thrombophlebitis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control
D000925:Anticoagulants; D000991:Antithrombins; D003278:Contraceptives, Oral, Hormonal; D011486:Protein C; C095381:factor V Leiden; D005165:Factor V
Síndrome de resistencia a la proteína C activada.